After a desperate, deadly year of coronavirus, the UK's vaccination programme has delivered first doses to 15 million of the oldest and most vulnerable.
A spotlight on the reaction in the U.K. to Pfizer’s COVID-19 vaccine as well as the logistical challenges to administering it to the general public.
The dean of the Brown University School of Public Health speaks to ABC News about the complexities of distributing the vaccine and the challenge of convincing people it’s safe to get.
Every vaccine bought for the UK has been on the assumption that just 30 million people - less than half the population - will get it.
Two COVID-19 vaccines being tested in the UK have moved on to the third phase of trials, marking a significant step forward in the development process.
Professor Peter Horby, Professor of Emerging Infectious Diseases and Global Health, has said that dexamethasone is the 'only drug shown to reduce mortality'.